N-succinimidyl-5-(2-pyridyldithio)valerate | 317331-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-succinimidyl-5-(2-pyridyldithio)valerate
• 英文别名: (2,5-dioxopyrrolidin-1-yl) 5-(pyridin-2-yldisulfanyl)pentanoate
• CAS: 317331-86-5
• 化学式: C₁₄H₁₆N₂O₄S₂
• 分子量: 340.424
• InChiKey: ABQGFYSYSCHJNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20130123465A1

  公开（公告）日：2013-05-16

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供了MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，其具有C-末端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接剂连接到配体上。相关的结合物可以定向特定的细胞类型，以提供治疗效益。
• Desmosine derivatives and reagent for preparing artificial antigens
  申请人：JAPAN TOBACCO INC.

  公开号：EP0196007A2

  公开（公告）日：1986-10-01

  A novel desmosine derivative, which is useful for preparing a desmosine artificial antigen, has an activated, disulfide bond on the side chain at 3 or 5 position of the pyridinium ring. The derivative can combine with a polymer having thiel groups by a disulfide bond to form the effective artificial antigen.

  一种新型去氨腺苷衍生物可用于制备去氨腺苷人工抗原，它在吡啶鎓环的 3 或 5 位侧链上有一个活化的二硫键。该衍生物可通过二硫键与具有巯基的聚合物结合，形成有效的人工抗原。
• Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1391213A1

  公开（公告）日：2004-02-25

  The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates contain maytansinoids as cytotoxic compounds, and preferred chemotherapeutic agents are taxanes.

  本发明涉及癌症治疗中 CD44 特异性抗体与细胞毒性化合物和化疗剂共轭物的联合使用、包含此类化合物和/或化疗剂的药物组合物以及癌症治疗方法。优选的共轭物含有作为细胞毒性化合物的麦他霉素，优选的化疗剂是紫杉类。
• Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1417974A1

  公开（公告）日：2004-05-12

  The invention relates to the combined use of conjugates of antibodies with cytotoxic compounds and radiotherapy in cancer therapy, pharmaceutical compositions comprising such compounds, and methods of cancer treatment. In a preferred embodiment, the antibody is specific for the tumor-associated antigen CD44v6 and linked to a maytansinoid. The radiotherapy may be external beam radiotherapy or radioimmunotherapy.

  本发明涉及在癌症治疗中抗体与细胞毒性化合物和放疗的结合使用、包含此类化合物的药物组合物以及癌症治疗方法。在一个优选的实施方案中，抗体对肿瘤相关抗原 CD44v6 具有特异性，并与一种 maytansinoid 连接。放射治疗可以是体外放射治疗或放射免疫治疗。
• Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus
  申请人：Seattle Genetics, Inc.

  公开号：US10000555B2

  公开（公告）日：2018-06-19

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供的 MeVal-Val-Dil-Dap-Phe (MMAF) Auristatin 肽类似物具有 C 端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接体连接到配体上。相关共轭物可靶向特定细胞类型，提供治疗效果。